A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI Community,

Happy 2026!

Since last connecting through this newsletter, SOFIE is pleased to share that our Phase 3 [18F]FAPI-74 diagnostic studies, FAPI-GO (FAPI in Gastroesophageal Oncology, NCT07217704) and FAPI-PRO (FAPI in Precision Imaging of Pancreatic Cancer, NCT07217717) are both activated with patient recruitment well underway. The clinical trials are planned for 18 sites with an estimated enrollment of 200 subjects over a 24-month period.

I was honored to participate in the 8th Theranostics World Congress held in Cape Town, South Africa, earlier this year. FAP targeting was a hot topic and I was buoyed by all the engagement about its future directions. Members of our FAPI team will be attending a slate of scientific meetings this spring.  Please see details below – we would love to see you in person!

We are excited to kick off another year with a focus on further educating the community about the potential of the FAP biomarker.  Let us know what you’d like to know more about!

– Sherly Mosessian, Ph.D., Chief Scientific Officer

Sherly Mosessian, Ph.D.

[18F]FAPI-74 CLINICAL DEVELOPMENT UPDATE

Q1 2026 Clin Dev Pipeline

FAPI ON THE MOVE

A member of SOFIE’s FAPI team will attend the spring meetings listed below. If you are attending, we would love to meet you and share more about our FAPI program.

FAPI Events

PUBLICATION HIGHLIGHTS

Each newsletter will feature recent FAPI publications.

90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis

J Nucl Med. 2026 Feb 19

Ensuring enantiomeric consistency in FAPI radiopharmaceuticals: comparative analysis of (S)- and (S/R)-FAPI-46/-74 confirms pharmacological equivalence

EJNMMI Radiopharm Chem. 2026 Feb 28

Reliability and Practicability of FAP-RADS Version 1.0

Revealing Reliability and Practicability of FAP-RADS Version 1.0 for Structured Reporting of FAPI Imaging in Pulmonary and Urothelial Carcinoma

J Nucl Med. 2026 Feb 19

FAPI OUTREACH PROGRAM

Join us in advancing the frontier of molecular imaging through the FAPI Outreach Program

SOFIE is continuing to accept applications for our FAPI Outreach Program. This program aims to raise awareness and foster collaboration in the field of molecular imaging, specifically focusing on Fibroblast Activation Protein Inhibitor (FAPI) studies. This program seeks to engage with healthcare professionals, researchers, and the broader community to share knowledge, advancements, and the potential impact of FAPI in diagnostic and therapeutic applications.

*GE Healthcare licensed products and regions are accepting new applications.

Copyright 2026 SOFIE CO. / ITHERANOSTICS INC. (21000 Atlantic Blvd. Suite 730  Dulles, VA  20166) all rights reserved.  The text or images in the newsletter may not be copied or distributed without prior permission of SOFIE. The SOFIE logo is a registered trademark of SOFIE CO. / ITHERANOSTICS INC., in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners. You have received this mail because you have subscribed for a newsletter at www.sofie.com or because you are an existing client or partner of SOFIE. If you no longer wish to receive these emails, click here to opt out.  This newsletter is meant to serve as an informational document as a service to our customers. The content or material provided is for informational purposes only and should and should not be construed as medical, legal, financial, investment, or other professional advice or opinion. SOFIE does not offer personalized medical advice or patient-specific treatment advice.